{'fraction_non_alphanumeric': 0.06308100929614874, 'fraction_numerical': 0.029216467463479414, 'mean_word_length': 4.730038022813688, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Insulin attenuates formalin-induced nociceptive response in mice through a mechanism that is deranged by diabetes mellitus.

Although hypoglycemic doses of insulin (0.24-7.5 U/kg s.c.) did not significantly change acetic acid-induced writhing in mice, they dose-dependently attenuated formalin-induced nociceptive responses, and their effects were more potent on the second phase (ID50 = .62 U/kg) than on the first (ID50 > 7.5 U/kg). Intracerebroventricular doses of insulin (250-1000 microU/animal) mimicked the effects of the s.c. dose, but caused little change in blood glucose levels. The antinociceptive activity of insulin (0.75 U/kg, s.c.) in the formalin test was significantly inhibited by naloxone (10 mg/kg i.p., an opiate receptor antagonist), sulpiride (10 mg/kg i.p., a dopamine 2 receptor antagonist), pindolol (1 mg/kg i.p., a 5-hydroxytryptamine 1 receptor antagonist) and ketanserin (1 mg/kg i.p., a 5-hydroxytryptamine 2 receptor antagonist), but not by 3-tropanyl-indole-3-carboxylate (1 mg/kg i.p., a 5-hydroxytryptamine 3 receptor antagonist). Insulin also exerted antinociception in streptozotocin-induced diabetic mice and genetically diabetic db/db mice which, however, were less sensitive (ID50s around 7.5 U/kg) to the of insulin effect than normal mice. The results suggest that insulin attenuates chronic rather than acute pains through a mechanism mediated by dopamine, 5-hydroxytryptamine and opioids. The antinociceptive pathway appears to be deranged by diabetes mellitus.